Ha-Rim Lee

Global Economic News

YPOSKESI, a French CMO company for cell and gene medicines, which was acquired by the investment firm SK in March, has started expanding its facilities to become an advanced biopharmaceutical production base.

SK announced that Yposkesi has invested 58 million euros (US$69.6 million) and started construction of the high-tech second production plant for cell and gene medicines.

The new plant is 5,000 square meters, will be constructed according to cGMP standard, which is the America/Europe Good Manufacturing Practice (GMP). Bioreactor for mass production of gene medicines, production facilities for pharmaceutical raw materials and QM Institute will be placed in.

It will be built in Genopole, where the first plant is located. When it is completed in 2023 and fully operated, Yposkesi will be able to have mass-produce capacity of 10,000 square meters, which is twice the current level and the largest in Europe.

Yposkesi’s new production facilities are expected to be a global production source for high-tech cell and gene medicines, especially for rare diseases with a high fatality rate.